About loncastuximab tesirine
CD19-directed antibody-drug conjugate
Used for
- Treats adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments.
Usual adult dose
0.15 mg/kg intravenously every three weeks for two cycles, then 0.075 mg/kg every three weeks; continue until progression or unacceptable toxicity.
Common side effects
- Low blood counts
- Swelling or fluid retention
- Fatigue
- Nausea
Important warnings
- Can cause serious low blood counts and infections.
- May cause fluid retention, including around the heart or lungs.
- Can cause skin reactions and sensitivity to sunlight.
- Avoid live vaccines during treatment.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 10 months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for three months after the last dose.
Interactions
- No specific clinically significant drug interactions are established; review all medicines with the treatment team.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.